Pooled retrospective analysis of 70 mg erenumab in episodic and chronic migraine: a two tertiary headache centers experience during clinical practice

Erenumab is a monoclonal antibody, targeted against the calcitonin gene-related peptide (CGRP) receptor. Clinical studies have demonstrated prophylactic efficacy in both episodic (EM) and chronic migraine (CM). The aim of the present study is to evaluate the efficacy of treatment in tertiary headach...

Descripción completa

Detalles Bibliográficos
Autores principales: Storch, P., Burow, P., Möller, B., Kraya, T., Heintz, S., Politz, N., Naegel, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9300569/
https://www.ncbi.nlm.nih.gov/pubmed/34406609
http://dx.doi.org/10.1007/s13760-021-01770-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9300569/
https://www.ncbi.nlm.nih.gov/pubmed/34406609
http://dx.doi.org/10.1007/s13760-021-01770-7

Ejemplares similares